Clinical outcome of patients diagnosed with myelodysplastic syndrome-unclassifiable (MDS-U): single center experience

Firas Baidoun, Dong Chen, Mrinal Patnaik, Naseema Gangat, Kebede Begna, Michelle Elliott, William Hogan, Mark Litzow, Aref Al-Kali

Research output: Contribution to journalArticlepeer-review

2 Scopus citations


Myelodysplastic syndrome unclassifiable (MDS-U) is a small subtype of myelodysplastic syndromes (MDS). However, rare literature exists in terms of natural progression and clinical outcome of patients with MDS-U. In the present study, we investigated the characteristics and the clinical outcomes of patients categorized as MDS-U based on 2008 World Health Organization criteria (WHO) in a single center comparing to other MDS groups. Out of eight hundred and two patients who met WHO criteria for MDS at our institution, ninety patients (11%) were initially classified as MDS-U. Upon pathological review, only half of the cases were confirmed to be MDS-U. With follow up, half of the MDS-U cases were reclassified to another subtype. We found neither significant difference in median overall survival nor in risk of transformation to acute myeloid leukemia when comparing MDS-U to other MDS groups. Additional larger studies are needed to confirm our results.

Original languageEnglish (US)
Pages (from-to)2483-2487
Number of pages5
JournalLeukemia and Lymphoma
Issue number10
StatePublished - Aug 24 2019


  • Myelodysplastic syndrome
  • World Health Organization
  • overall survival
  • unclassifiable

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research


Dive into the research topics of 'Clinical outcome of patients diagnosed with myelodysplastic syndrome-unclassifiable (MDS-U): single center experience'. Together they form a unique fingerprint.

Cite this